Related Experiment Video
Updated: May 18, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Postnatal administration of IL-1Ra exerts neuroprotective effects following perinatal inflammation and/or
Sylvie Girard1, Hugues Sébire, Marie-Elsa Brochu
1Laboratoire de Neurologie Pédiatrique, Département de Pédiatrie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada. sylvie.girard@manchester.ac.uk
Insights
Interleukin-1 receptor antagonist (IL-1Ra) protects newborns from brain damage caused by inflammation or hypoxia-ischaemia. Postnatal IL-1Ra treatment improved neurobehavioral outcomes and preserved brain development in neonatal injury models.
Area of Science:
- Neuroscience
- Developmental Biology
- Immunology
Background:
- Neonatal brain injury, particularly in premature infants, leads to lasting neurodevelopmental deficits.
- Pro-inflammatory cytokines, such as IL-1β, are key mediators in neonatal brain damage pathways.
- Targeting inflammatory pathways presents a promising therapeutic strategy for neonatal brain protection.
Purpose of the Study:
- To evaluate the neuroprotective potential of postnatal interleukin-1 receptor antagonist (IL-1Ra) administration.
- To investigate IL-1Ra efficacy in an animal model simulating common neonatal insults: prenatal inflammation and/or postnatal hypoxia-ischaemia (HI).
Main Methods:
- Animal model of perinatal brain injury involving prenatal lipopolysaccharide (LPS) exposure and/or postnatal HI.
- Postnatal systemic administration of IL-1Ra.
- Assessment of motor function, exploratory behavior, neural stem cell populations, myelin integrity, gliosis, and neurobehavioral impairment.
Main Results:
- Postnatal IL-1Ra administration preserved motor function and exploratory behavior following either prenatal LPS or postnatal HI.
- Combined prenatal LPS and postnatal HI-induced brain damage was significantly alleviated by IL-1Ra.
- IL-1Ra treatment protected neural stem cells, prevented myelin loss, reduced gliosis, and improved neurobehavioral outcomes.
Conclusions:
- Postnatal IL-1Ra is a potential therapeutic agent for neonatal brain injury.
- IL-1Ra effectively mitigates brain damage and neurobehavioral deficits resulting from both prenatal inflammation and postnatal HI.
- This study supports the therapeutic potential of targeting IL-1 pathways for neonatal brain protection, including treating effects of prenatal inflammatory stressors.
Abstract:
New therapeutic strategies are needed to protect neonates, especially premature newborns, against brain injury and associated neurobehavioral deficits. The role of pro-inflammatory cytokines, especially IL-1β, in the pathophysiological pathway leading to neonatal brain damage is increasingly recognized and represents an attractive therapeutic target. We investigated the therapeutic potential of postnatal systemic administration of the interleukin (IL)-1 receptor antagonist (IL-1Ra) in an animal model of perinatal brain injury using the insults most common to human neonates, i.e. prenatal exposure to inflammation and/or postnatal hypoxia-ischaemia (HI). We found that postnatal administration of IL-1Ra preserved motor function and exploratory behavior after either prenatal exposure to inflammatory agent lipopolysaccharide (LPS) or postnatal HI insult. The deleterious effect of combined prenatal LPS and postnatal HI on brain development was also alleviated by administration of IL-1Ra, as seen by the protected neural stem cell population, prevention of myelin loss in the internal capsule, decreased gliosis, and decreased neurobehavioral impairment. This study showed the distinct pattern of functional deficits induced by prenatal inflammation as compared to postnatal HI and the therapeutic potential of IL-1Ra administration against neonatal brain injury. Furthermore, our results highlight the potential for postnatal treatment of prenatal inflammatory stressors.
